Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 3/20 | 0.58 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | SYK | P43405 | 4/20 | 0.47 |
| ▸ | JAK3 | P52333 | 4/20 | 0.45 |
| ▸ | BTK | Q06187 | 3/20 | 0.45 |
| ▸ | TTK | P33981 | 3/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | PAK4 | O96013 | 1/20 | 0.44 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.43 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1018234 | 1.00 | PTK2 (0.58) | PTK2EGFRSYKJAK3BTK | |
| SCHEMBL1017177 | 1.00 | PTK2 (0.58) | PTK2EGFRSYKJAK3BTK | |
| SCHEMBL4376418 | 0.87 | SYK (0.64) | PTK2EGFRSYKJAK3BTK | |
| SCHEMBL1018255 | 0.87 | SYK (0.64) | PTK2EGFRSYKJAK3BTK | |
| SCHEMBL1073042 | 0.87 | SYK (0.64) | PTK2EGFRSYKJAK3BTK | |
| SCHEMBL1021471 | 0.85 | PTK2 (0.47) | PTK2EGFRSYKJAK3BTK | |
| SCHEMBL12085426 | 0.77 | PTK2 (0.49) | PTK2EGFRJAK3TTKJAK2 | |
| SCHEMBL1018558 | 0.76 | PTK2 (0.57) | PTK2EGFRSYKJAK3BTK | |
| SCHEMBL3280599 | 0.76 | PTK2 (0.57) | PTK2EGFRJAK3BTKTTK | |
| SCHEMBL27930633 | 0.75 | PTK2 (0.52) | PTK2EGFRJAK3BTKTTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271631-A2 | INHIBITORS OF PROTEIN KINASES | Portola Pharmaceuticals, Inc. (US) | 2011-01-12 | — | — | EP | claimed |
| US-20090298823-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | claimed |
| WO-2009131687-A2 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | claimed |
| EP-2271631-B1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARM INC (US) | 2018-07-04 | — | — | EP | disclosed |
| US-9139581-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139581-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139581-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20130029944-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8258144-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-8258144-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-8258144-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| EP-2271631-A2 | INHIBITORS OF PROTEIN KINASES | Portola Pharmaceuticals, Inc. (US) | 2011-01-12 | — | — | EP | disclosed |
| US-20090298823-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090298823-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090298823-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| WO-2009131687-A2 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009131687-A2 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029944-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK2 | PTK2 17/4885EGFR 805/4885SYK 1/4885 |
| US-20090298823-A1 | Inhibitors of protein kinases | SYK, BTK, JAK2 | PTK2 17/4885EGFR 805/4885SYK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.